You are currently viewing a new version of our website. To view the old version click .
Medical Sciences Forum
  • Abstract
  • Open Access

1 November 2022

Development of In Situ Gel Containing Phytoconstituents for the Treatment of Mouth Ulcers †

and
School of Pharmaceutical Sciences, Atmiya University, Gujarat 360005, India
*
Author to whom correspondence should be addressed.
Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: https://ecmc2022.sciforum.net/.
This article belongs to the Proceedings The 8th International Electronic Conference on Medicinal Chemistry

Abstract

An ulcer that develops on the mucosal surface of the oral cavity is known as a mouth ulcer, also known as an oral ulcer or a mucosal ulcer. A mucus membrane ulcer is an open sore that is distinguished by the removal of inflammatory dead tissue. The most typical type of oral ulcer is aphthous stomatitis. This investigation focuses on temperature-sensitive in situ gel formulations, which change their phase in response to body heat from liquid to semisolid gel. These are easily administered into the buccal cavity at the ulcer site and are a free-flowing liquid at room temperature. Utilizing various polymers, a temperature-sensitive in situ gel comprising phytoconstituents was developed utilising the cold technique. To optimise various types and concentrations of polymers, including carbopol, Poloxamer 188 (P 188), Poloxamer 407 (P 407), and others, preliminary research was conducted. For the formulation, 20% P 188 and 15% P 407 were employed because there is a correlation between the amount of poloxamers and thermogelling transition temperatures (Tsol-gel). A blend of phytoconstituents found in the extracts of Glycyrrhizin glabra and Psidium guava is used in the formulation of mouth ulcers because, as we know, they have fewer negative effects than synthetic chemicals. The outcomes demonstrated improved homogeneity, stability, gelation temperature, and spreadability for the developed product, which was regarded as satisfactory. The created formulation can also lessen dose variation and treat oral ulcers in the most effective way, with improved patient compliance.

Supplementary Materials

The presentation material of this work is available online at https://www.mdpi.com/article/10.3390/ECMC2022-13438/s1.

Author Contributions

Conceptualization, K.G. and P.R.; methodology K.G.; software, K.G.; validation, K.G. and P.R.; formal analysis, K.G.; investigation K.G.; resources, P.R.; data curation, K.G.; writing—original draft preparation, P.R.; writing—review and editing, K.G. and P.R.; visualization P.R.; supervision, K.G.; project administration, K.G.; funding acquisition, P.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.